- Mizuho rides to the rescue after a report from SA contributor Gravity Research tanked Avanir Pharmaceuticals (AVNR) Wednesday.
- Analyst Mario Corso thinks Gravity is "off the mark."
- Mizuho apparently has a different take on Nuedexta off-label marketing and AVNR's chances in a patent lawsuit.
- AVNR +2.5% premarket
Mizuho comes to Avanir's defense after sell-off
Sep 12 2013, 09:18 ET